Second All-Oral Hep C Treatment Available: Less Expensive
Share
Follow Us
The Editors at Hepatitis Central
November 13, 2014
Olysio has been approved, in combination with Sovaldi, for the treatment of Hepatitis C. It is approximately $30,000 less than Harvoni (both of which consist of 12 weeks of therapy).
J&J Wins U.S. Approval for Hepatitis C Combo With Gilead
By Anna Edney
Johnson & Johnson (JNJ) won U.S. approval for its hepatitis C drug Olysio to be used in combination with Gilead Sciences Inc. (GILD)’s Sovaldi, making it the second all-oral treatment available for the most common form of the virus.
The Food and Drug Administration cleared the once-daily treatment for patients with hepatitis C genotype 1, J&J said yesterday in a statement. The combination allows Olysio to be used without the standard therapies including interferon, an injection that sometimes has flu-like side effects.
Continue reading this entire article:
http://www.bloomberg.com/news/2014-11-05/j-j-wins-u-s-approval-for-hepatitis-c-combo-with-gilead.html
